| Literature DB >> 27097827 |
Andrea C Tricco1,2, Huda M Ashoor1, Roberta Cardoso1, Heather MacDonald1, Elise Cogo1, Monika Kastner1,2, Laure Perrier3, Ann McKibbon4, Jeremy M Grimshaw5,6, Sharon E Straus7,8.
Abstract
BACKGROUND: Knowledge translation (KT, also known as research utilization, and sometimes referring to implementation science) is a dynamic and iterative process that includes the synthesis, dissemination, exchange, and ethically sound application of knowledge to improve health. A KT intervention is one which facilitates the uptake of research. The long-term sustainability of KT interventions is unclear. We aimed to characterize KT interventions to manage chronic diseases that have been used for healthcare outcomes beyond 1 year or beyond the termination of initial grant funding.Entities:
Keywords: Adherence; Healthcare utilization; Implementation; Knowledge translation; Long-term; Maintenance; Patient education; Quality improvement; Self-management; Sustainability
Mesh:
Year: 2016 PMID: 27097827 PMCID: PMC4839064 DOI: 10.1186/s13012-016-0421-7
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Fig. 1Study flow. Details the flow of information through the different phases of the review; maps out the number of records identified, included and excluded, and the reasons for their exclusion
Fig. 2Word cloud displaying sustainability terminology. The most commonly used terminology in the 103 included studies, with the size of the terms in the word cloud corresponding to the frequency of their use
Summary of study characteristics
| Characteristic | Number (% out of 62) |
|---|---|
| Year of publication | |
| 1979 to 1986 | 5 (8 %) |
| 1987 to 1994 | 2 (3 %) |
| 1995 to 2002 | 15 (24 %) |
| 2003 to 2010 | 32 (52 %) |
| 2011 | 4 (6 %) |
| 2012 | 4 (6 %) |
| Study period | |
| 1970 to 1980 | 4 (6 %) |
| 1981 to 1990 | 3 (5 %) |
| 1991 to 2000 | 21 (34 %) |
| 2001 to 2010 | 17 (27 %) |
| Not reported | 17 (27 %) |
| Geographic region of conduct | |
| North America | 39 (63 %) |
| Europe | 16 (26 %) |
| Australia | 4 (6 %) |
| Asia | 2 (3 %) |
| South America | 1 (2 %) |
| Study design | |
| Randomized controlled trial | 31 (50 %) |
| Cohort | 24 (39 %) |
| Cluster-randomized controlled trial | 2 (3 %) |
| Non-randomized controlled trial | 2 (3 %) |
| Case control | 1 (2 %) |
| Controlled before-after study | 1 (2 %) |
| Quasi-randomized controlled trial | 1 (2 %) |
| Funding sources | |
| Not reported | 19 (24 %) |
| Governmental organization | 18 (23 %) |
| Research funding body | 16 (21 %) |
| Commercial organization | 11 (14 %) |
| Healthcare provider organization | 6 (8 %) |
| Charitable trust | 3 (4 %) |
| Voluntary body | 2 (3 %) |
| Mixed | 2 (3 %) |
| Other | 1 (1 %) |
| Duration of knowledge translation intervention (in weeks) | |
| 61 to 104 | 38 (61 %) |
| 104 to 157 | 10 (16 %) |
| 157 to 209 | 4 (6 %) |
| 209 to 261 | 3 (5 %) |
| 261 to 313 | 0 (0 %) |
| 313 to 365 | 1 (2 %) |
| 365 to 417 | 1 (2 %) |
| 417 to 470 | 0 (0 %) |
| 470 to 522 | 5 (8 %) |
| Setting | |
| Multi-site | 36 (58 %) |
| Single-site | 25 (40 %) |
| Not reported | 1 (2 %) |
| Number of study arms | |
| 2 | 51 (82 %) |
| 3 | 4 (6 %) |
| 4 | 6 (10 %) |
| 8 | 1 (2 %) |
| Follow-up duration in weeks | |
| 52 to 104 | 34 (55 %) |
| 104 to 157 | 11 (18 %) |
| 157 to 209 | 5 (8 %) |
| 209 to 261 | 4 (6 %) |
| 261 to 313 | 0 (0 %) |
| 313 to 365 | 1 (2 %) |
| 365 to 417 | 1 (2 %) |
| 417 to 470 | 0 (0 %) |
| 470 to 522 | 5 (8 %) |
| Not reported | 1 (2 %) |
Summary of patient characteristics
| Total number of patients 260,688, mean per study 4495 | |
|---|---|
| Age range: 18 to 99 | |
| Mean % female: 47.85 (11 NR) | |
| Patient characteristics | Number (% out of 62) |
| Chronic disease (multiple reported per study) | |
| Diabetes | 26 (34 %) |
| Cardiovascular diseases | 21 (28 %) |
| Hypertension | 12 (16 %) |
| Chronic Obstructive Pulmonary Disease | 7 (9 %) |
| Asthma | 3 (4 %) |
| Cancer | 3 (4 %) |
| Arthritis | 2 (3 %) |
| Unspecified chronic illness | 1 (1 %) |
| Renal disease | 1 (1 %) |
| Number of conditions | |
| Single condition | 54 (87 %) |
| Multiple conditions | 8 (13 %) |
Summary of interventions
| Intervention characteristics | Number (%) |
|---|---|
| Knowledge translation interventions/control out of 409 total | |
| Patient education | 83 (20 %) |
| Self-management | 70 (17 %) |
| Control/usual care | 58 (14 %) |
| Case management | 38 (9 %) |
| Team change | 38 (9 %) |
| Clinician education | 26 (6 %) |
| Reminders | 23 (6 %) |
| Social support | 16 (4 %) |
| Motivational interviewing | 15 (4 %) |
| Audit and feedback | 13 (3 %) |
| Financial incentive | 11 (3 %) |
| Electronic patient registry | 8 (2 %) |
| Continuous quality improvement | 5 (1 %) |
| Facilitated relay | 5 (1 %) |
| Level of the intervention out of 339 total | |
| Patient | 197 (58 %) |
| Health system | 94 (28 %) |
| Healthcare personnel | 48 (14 %) |
| Target of the intervention (multiple reported per study) out of 316 total | |
| Patient | 236 (75 %) |
| Healthcare provider(s) | 49 (16 %) |
| Family | 11 (3 %) |
| Health centre(s) | 10 (3 %) |
| Community | 6 (2 %) |
| Not reported | 2 (1 %) |
| Other | 1 (0.3 %) |
| Fidelity of the intervention out of 62 studies | |
| No | 59 (95 %) |
| Yes | 3 (5 %) |
| Adaptation of the intervention out of 62 studies | |
| No | 56 (90 %) |
| Yes | 6 (10 %) |
Summary of outcomes
| Outcome characteristics | Number (%) |
|---|---|
| Type of outcome out of 628 total | |
| Healthcare utilization | 142 (23 %) |
| Blood pressure | 65 (10 %) |
| Glycemic control | 47 (7 %) |
| Function | 38 (6 %) |
| Overall mortality and cause-specific mortality | 38 (6 %) |
| Cholesterol | 34 (5 %) |
| Compliance | 34 (5 %) |
| Cardiovascular health | 34 (5 %) |
| Body mass index | 31 (5 %) |
| Pulmonary function | 16 (3 %) |
| Renal function | 15 (2 %) |
| Cost | 13 (2 %) |
| Diet | 11 (2 %) |
| Satisfaction | 11 (2 %) |
| Mental health | 10 (2 %) |
| Quality of life | 8 (1 %) |
| Attitude | 7 (1 %) |
| Behaviour | 6 (1 %) |
| Health status | 6 (1 %) |
| Knowledge | 6 (1 %) |
| Safety | 6 (1 %) |
| Smoking | 5 (1 %) |
| Vision health | 5 (1 %) |
| Cognition | 4 (1 %) |
| Disease severity | 4 (1 %) |
| Employment | 4 (1 %) |
| Motivation | 4 (1 %) |
| Vision | 4 (1 %) |
| Alcohol intake | 3 (0 %) |
| Barrier/facilitator | 3 (0 %) |
| Nerve function | 3 (0 %) |
| Self-efficacy | 3 (0 %) |
| Level of care | 2 (0 %) |
| Comorbidity | 1 (0 %) |
| Discontinuation | 1 (0.2 %) |
| Feasibility | 1 (0.2 %) |
| Fidelity | 1 (0.2 %) |
| Liver function | 1 (0.2 %) |
| Pain | 1 (0.2 %) |
| Level of outcome out of 616 total | |
| Patient level | 377 (61 %) |
| System level | 191 (31 %) |
| Both | 48 (8 %) |